Nyxoah (NASDAQ:NYXH) announced the successful commercial launch of its Genio bilateral neurostimulation system in the Netherlands on Dec. 17, 2025.
The first implants were completed at OLVG West in Amsterdam and Zuyderland Hospital in Heerlen, marking a significant milestone in the company’s European rollout.
The Genio system is designed to provide bilateral nerve stimulation as an alternative to traditional CPAP treatments for obstructive sleep apnea (OSA) patients who struggle to tolerate CPAP.
Notably, the device does not require an implanted battery and offers full-body MRI compatibility with both 1.5T and 3T machines.
Additionally, it features an externally powered activation chip that allows for future upgrades, adding long-term value for patients.
Nyxoah emphasized that the successful early implants validate Genio’s potential as a sustainable treatment option for sleep apnea sufferers, providing a non-invasive and easily upgradeable solution.
The company views the Netherlands launch as an essential step in expanding its presence across Europe and offering a next-generation treatment for the millions of OSA patients who need alternatives to traditional CPAP therapy